127 related articles for article (PubMed ID: 35822453)
1. Outcomes of curative treatment for head and neck squamous cell carcinoma in very elderly adults ≥80 years old.
Wilson T; Fleischer L; Patel S; Bhatnagar A; Ahmad N; Kubicek G
Head Neck; 2022 Nov; 44(11):2370-2377. PubMed ID: 35822453
[TBL] [Abstract][Full Text] [Related]
2. Prognostic value of maximum standardized uptake value measured by pretreatment 18F-FDG PET/CT in locally advanced head and neck squamous cell carcinoma.
Cacicedo J; Fernandez I; Del Hoyo O; Navarro A; Gomez-Iturriaga A; Pijoan JI; Martinez-Indart L; Escudero J; Gomez-Suarez J; de Zarate RO; Perez JF; Bilbao P; Rades D
Clin Transl Oncol; 2017 Nov; 19(11):1337-1349. PubMed ID: 28540535
[TBL] [Abstract][Full Text] [Related]
3. Radiotherapy for geriatric head-and-neck cancer patients: what is the value of standard treatment in the elderly?
Haehl E; Rühle A; David H; Kalckreuth T; Sprave T; Stoian R; Becker C; Knopf A; Grosu AL; Nicolay NH
Radiat Oncol; 2020 Feb; 15(1):31. PubMed ID: 32019576
[TBL] [Abstract][Full Text] [Related]
4. c-Met expression is a marker of poor prognosis in patients with locally advanced head and neck squamous cell carcinoma treated with chemoradiation.
Baschnagel AM; Williams L; Hanna A; Chen PY; Krauss DJ; Pruetz BL; Akervall J; Wilson GD
Int J Radiat Oncol Biol Phys; 2014 Mar; 88(3):701-7. PubMed ID: 24521684
[TBL] [Abstract][Full Text] [Related]
5. The value of primary and adjuvant radiotherapy for cutaneous squamous cell carcinomas of the head-and-neck region in the elderly.
Haehl E; Rühle A; Klink R; Kalckreuth T; Sprave T; Gkika E; Zamboglou C; Meiß F; Grosu AL; Nicolay NH
Radiat Oncol; 2021 Jun; 16(1):105. PubMed ID: 34118984
[TBL] [Abstract][Full Text] [Related]
6. Survival outcomes of perineural spread in head and neck cutaneous squamous cell carcinoma.
Phung D; Ahmadi N; Gupta R; Clark JR; Wykes J; Ch'ng S; Elliott MS; Palme CE; Shannon K; Wu R; Lee JH; Low TH
ANZ J Surg; 2022 Sep; 92(9):2299-2304. PubMed ID: 35866314
[TBL] [Abstract][Full Text] [Related]
7. Toxicity and outcomes in combined modality treatment of head and neck squamous cell carcinoma: cisplatin versus cetuximab.
Ye AY; Hay JH; Laskin JJ; Wu JS; Ho CC
J Cancer Res Ther; 2013; 9(4):607-12. PubMed ID: 24518704
[TBL] [Abstract][Full Text] [Related]
8. The impact of cumulative dose of cisplatin on outcome of patients with head and neck squamous cell carcinoma.
Al-Mamgani A; de Ridder M; Navran A; Klop WM; de Boer JP; Tesselaar ME
Eur Arch Otorhinolaryngol; 2017 Oct; 274(10):3757-3765. PubMed ID: 28755023
[TBL] [Abstract][Full Text] [Related]
9. Prognostic significance of head and neck spindle cell carcinoma.
Patel AM; Choudhry HS; Desai AD; Shah VP; Patel P; Eloy JA; Roden DF; Fang CH
Head Neck; 2023 Mar; 45(3):685-696. PubMed ID: 36584171
[TBL] [Abstract][Full Text] [Related]
10. Salvage Surgery for Recurrence after Radiotherapy for Squamous Cell Carcinoma of the Head and Neck.
Elbers JBW; Al-Mamgani A; van den Brekel MWM; Jóźwiak K; de Boer JP; Lohuis PJFM; Willems SM; Verheij M; Zuur CL
Otolaryngol Head Neck Surg; 2019 Jun; 160(6):1023-1033. PubMed ID: 30526317
[TBL] [Abstract][Full Text] [Related]
11. Outcomes of curative (chemo)radiotherapy for patients with non-p16 positive head and neck squamous cell carcinoma who are borderline for curative treatment.
Xing D; Tiong A; Bressel M; Rischin D; Tran P; Corry J
J Med Imaging Radiat Oncol; 2020 Apr; 64(2):271-278. PubMed ID: 32037733
[TBL] [Abstract][Full Text] [Related]
12. Prognostic model for overall survival of head and neck cancer patients in the palliative phase.
Hoesseini A; Sewnaik A; van den Besselaar BN; Zhang J; van Leeuwen N; Hardillo JA; Baatenburg de Jong RJ; Offerman MPJ
BMC Palliat Care; 2024 Feb; 23(1):54. PubMed ID: 38395897
[TBL] [Abstract][Full Text] [Related]
13. Prognostic value of circulating biomarker score in advanced-stage head and neck squamous cell carcinoma.
Park MJ; Roh JL; Kim SB; Choi SH; Nam SY; Kim SY
Eur J Cancer; 2018 Mar; 92():69-76. PubMed ID: 29428866
[TBL] [Abstract][Full Text] [Related]
14. Development and validation of a novel prognostic score for elderly head-and-neck cancer patients undergoing radiotherapy or chemoradiation.
Rühle A; Stromberger C; Haehl E; Senger C; David H; Stoian R; Zamboglou C; Knopf A; Budach V; Grosu AL; Nicolay NH
Radiother Oncol; 2021 Jan; 154():276-282. PubMed ID: 33245947
[TBL] [Abstract][Full Text] [Related]
15. Phase III study of nivolumab alone or combined with ipilimumab as immunotherapy versus standard of care in resectable head and neck squamous cell carcinoma.
Zech HB; Moeckelmann N; Boettcher A; Muenscher A; Binder M; Vettorazzi E; Bokemeyer C; Schafhausen P; Betz CS; Busch CJ
Future Oncol; 2020 Dec; 16(36):3035-3043. PubMed ID: 32902312
[TBL] [Abstract][Full Text] [Related]
16. Pretreatment albumin level predicts survival in head and neck squamous cell carcinoma.
Lim WS; Roh JL; Kim SB; Choi SH; Nam SY; Kim SY
Laryngoscope; 2017 Dec; 127(12):E437-E442. PubMed ID: 28561532
[TBL] [Abstract][Full Text] [Related]
17. Association of Adjuvant Radiation Therapy With Survival in Patients With Advanced Cutaneous Squamous Cell Carcinoma of the Head and Neck.
Harris BN; Pipkorn P; Nguyen KNB; Jackson RS; Rao S; Moore MG; Farwell DG; Bewley AF
JAMA Otolaryngol Head Neck Surg; 2019 Feb; 145(2):153-158. PubMed ID: 30570645
[TBL] [Abstract][Full Text] [Related]
18. Concurrent cisplatin or cetuximab with radiotherapy in patients with locally advanced head and neck squamous cell carcinoma: A meta-analysis.
Tang WH; Sun W; Long GX
Medicine (Baltimore); 2020 Sep; 99(36):e21785. PubMed ID: 32899005
[TBL] [Abstract][Full Text] [Related]
19. Assessing the prognostic value of tumor-infiltrating CD57+ cells in advanced stage head and neck cancer using QuPath digital image analysis.
de Ruiter EJ; Bisheshar SK; de Roest RH; Wesseling FWR; Hoebers FJP; van den Hout MFCM; Leemans CR; Brakenhoff RH; de Bree R; Terhaard CHJ; Willems SM
Virchows Arch; 2022 Aug; 481(2):223-231. PubMed ID: 35451620
[TBL] [Abstract][Full Text] [Related]
20. A randomized phase 3 trial comparing nimotuzumab plus cisplatin chemoradiotherapy versus cisplatin chemoradiotherapy alone in locally advanced head and neck cancer.
Patil VM; Noronha V; Joshi A; Agarwal J; Ghosh-Laskar S; Budrukkar A; Murthy V; Gupta T; Mahimkar M; Juvekar S; Arya S; Mahajan A; Agarwal A; Purandare N; Rangarajan V; Balaji A; Chaudhari SV; Banavali S; Kannan S; Bhattacharjee A; D'Cruz AK; Chaturvedi P; Pai PS; Chaukar D; Pantvaidya G; Nair D; Nair S; Deshmukh A; Thiagarajan S; Mathrudev V; Manjrekar A; Dhumal S; Maske K; Bhelekar AS; Nawale K; Chandrasekharan A; Pande N; Goel A; Talreja V; Simha V; Srinivas S; Swami R; Vallathol DH; Dsouza H; Shrirangwar S; Turkar S; Abraham G; Thanky AH; Patel U; Pandey MK; Prabhash K
Cancer; 2019 Sep; 125(18):3184-3197. PubMed ID: 31150120
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
